Novavax finally submits its COVID-19 vaccine to the FDA. Is it too late?

It's finally here: After a series of delays in the lead-up to Novavax's COVID-19 vaccine filing with the FDA, the biotech has completed its emergency use authorization request.

Novavax on Monday said it filed NVX-CoV2373 for use in people 18 and older. NVX-CoV2373 is a protein-based shot that has demonstrated efficacy of about 90% against symptomatic disease in a large trial in the U.S. and Mexico, the biotech says.